EA200700292A1 - Полипептиды с повышенной экспрессией - Google Patents

Полипептиды с повышенной экспрессией

Info

Publication number
EA200700292A1
EA200700292A1 EA200700292A EA200700292A EA200700292A1 EA 200700292 A1 EA200700292 A1 EA 200700292A1 EA 200700292 A EA200700292 A EA 200700292A EA 200700292 A EA200700292 A EA 200700292A EA 200700292 A1 EA200700292 A1 EA 200700292A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cys2
cys1
polypeptide
cysteine
eed
Prior art date
Application number
EA200700292A
Other languages
English (en)
Other versions
EA010374B1 (ru
Inventor
Патрик Хоффманн
Силке Миттельштрасс
Енс Хеннеке
Тобиас Раум
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of EA200700292A1 publication Critical patent/EA200700292A1/ru
Publication of EA010374B1 publication Critical patent/EA010374B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагается составной полипептид, содержащий исходный полипептид и домен, усиливающий экспрессию (EED); упомянутый EED содержит первый и второй аминокислотные остатки цистеина Cys1 и Cys2, причем Cys1 располагается ближе к N-концу молекулы составного полипептида, чем Cys2, а Cys1 и Cys2 разделены полипептидным линкером, который свободен от цистеина и пролина; определяет длину, достаточную для того, чтобы позволить Cys1 и Cys2 образовать внутримолекулярную дисульфидную связь друг с другом; имеет гибкую полипептидную конформацию, по существу, свободную от вторичной полипептидной структуры в водном растворе; причем по крайней мере один из остатков Cys1 и Cys2 дериватизируется с помощью дериватизирующего компонента.
EA200700292A 2004-07-16 2005-07-15 Полипептиды с повышенной экспрессией EA010374B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016890 2004-07-16
PCT/EP2005/007748 WO2006008096A1 (en) 2004-07-16 2005-07-15 Expression-enhanced polypeptides

Publications (2)

Publication Number Publication Date
EA200700292A1 true EA200700292A1 (ru) 2007-06-29
EA010374B1 EA010374B1 (ru) 2008-08-29

Family

ID=35229693

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700292A EA010374B1 (ru) 2004-07-16 2005-07-15 Полипептиды с повышенной экспрессией

Country Status (12)

Country Link
US (1) US8518403B2 (ru)
EP (1) EP1769000B1 (ru)
JP (2) JP5014988B2 (ru)
KR (1) KR20070042967A (ru)
CN (1) CN101018809B (ru)
AU (1) AU2005263555B2 (ru)
CA (1) CA2570990C (ru)
EA (1) EA010374B1 (ru)
MX (1) MX2007000387A (ru)
NZ (1) NZ552745A (ru)
WO (1) WO2006008096A1 (ru)
ZA (1) ZA200610478B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
US8940298B2 (en) * 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
MX344076B (es) * 2008-06-30 2016-12-05 Esbatech Alcon Biomed Res Unit Polipeptidos funcionalizados.
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US20120034228A1 (en) * 2008-10-01 2012-02-09 Micromet Ag CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
PL2356153T3 (pl) * 2008-10-01 2016-11-30 Swoiste międzygatunkowo dwuswoiste przeciwciało jednołańcuchowe PSMAXCD3
EP3495000A1 (en) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
EP2448966B1 (en) * 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US8993715B2 (en) 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
MX354143B (es) 2009-12-02 2018-02-14 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
AU2012245260B2 (en) 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
EP3421488A3 (en) * 2012-03-14 2019-04-17 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN108289949B (zh) 2015-05-29 2022-04-12 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
KR20180050321A (ko) 2015-08-07 2018-05-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736A1 (en) 2017-02-20 2019-09-05 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
CN110668984B (zh) * 2019-12-03 2020-04-10 凯莱英医药集团（天津）股份有限公司 一种依特卡肽中间体及依特卡肽的合成方法
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO2001087925A2 (en) 2000-05-16 2001-11-22 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
AU6097100A (en) * 1999-07-13 2001-01-30 Regents Of The University Of Michigan, The Crosslinked dna condensate compositions and gene delivery methods
JP2004503512A (ja) * 2000-06-09 2004-02-05 アメリカ合衆国 免疫複合体の抗腫瘍活性を改善し、かつ、毒性を低減するリンカーのｐｅｇ化
AU2001268452B2 (en) * 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
PL206701B1 (pl) * 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
PL373566A1 (en) * 2001-11-08 2005-09-05 William R. Moyle Protein knobs
EA201000921A1 (ru) * 2007-11-30 2010-12-30 Бристол-Маерс Сквибб Компани Конъюгаты антител против rg-1

Also Published As

Publication number Publication date
EP1769000B1 (en) 2014-12-24
AU2005263555A1 (en) 2006-01-26
CA2570990A1 (en) 2006-01-26
MX2007000387A (es) 2007-03-28
CA2570990C (en) 2014-01-21
CN101018809B (zh) 2012-07-18
CN101018809A (zh) 2007-08-15
AU2005263555B2 (en) 2011-01-27
EP1769000A1 (en) 2007-04-04
KR20070042967A (ko) 2007-04-24
WO2006008096A1 (en) 2006-01-26
JP2008506659A (ja) 2008-03-06
JP2012144552A (ja) 2012-08-02
ZA200610478B (en) 2008-04-30
EA010374B1 (ru) 2008-08-29
NZ552745A (en) 2009-01-31
JP5014988B2 (ja) 2012-08-29
US8518403B2 (en) 2013-08-27
US20090053223A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
EA200700292A1 (ru) Полипептиды с повышенной экспрессией
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
AR054165A1 (es) Proteinas de union a il-6
DE602005008996D1 (de) Radiofluorierte peptide
EA200800535A1 (ru) Пептиды и соединения, которые связываются с рецептором
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
BR112015011317A2 (pt) métodos para preparar conjugados de proteínas contendo dissulfeto
EA200300644A1 (ru) Слитые белки glp-1
CO5611157A2 (es) Compuestos glp-1 unidos a polietilenglicol
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
ES2531480T3 (es) Péptidos derivados de la proteína bplp humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
CO5720212A1 (es) Composicion de anticuerpo her2
BRPI0209685B8 (pt) derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópico
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
ATE522563T1 (de) Verzweigte polyalkylenglykole
ES2677246T3 (es) Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
EA200870208A1 (ru) Конструкт однодоменного антитела
BR0312491A (pt) Processo para a telomerização de olefinas não-cìclicas
CY1110186T1 (el) Συνθεση ινσουλινοτροπου πεπτιδιου

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU